Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Complementary Medicines
Database
Language
Affiliation country
Publication year range
1.
Nutr Neurosci ; 24(1): 1-12, 2021 Jan.
Article in English | MEDLINE | ID: mdl-30822260

ABSTRACT

Background: Essential fatty acids (EFAs) and non-essential fatty acids (nEFAs) exert experimental and clinical neuroprotection in neurodegenerative diseases. The main EFAs, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), nEFAs, and oleic acid (OA) contained in olive and fish oils are inserted into the cell membranes, but the exact mechanism through which they exert neuroprotection is still unknown. Objectives and Methods: In this study, we assessed the fatty acids content and membrane fluidity in striatal rat synaptosomes after fatty acid-rich diets (olive- or a fish-oil diet, 15% w/w). Then, we evaluated the effect of enriching striatum synaptosomes with fatty acids on the oxidative damage produced by the prooxidants ferrous sulfate (FeSO4) or quinolinic acid (QUIN). Results and Discussion: Lipid profile analysis in striatal synaptosomes showed that EPA content increased in the fish oil group in comparison with control and olive groups. Furthermore, we found that synaptosomes enriched with fatty acids and incubated with QUIN or FeSO4 showed a significant oxidative damage reduction. Results suggest that EFAs, particularly EPA, improve membrane fluidity and confer antioxidant effect.


Subject(s)
Cell Membrane/metabolism , Corpus Striatum/metabolism , Fatty Acids/metabolism , Oxidative Stress , Synaptosomes/metabolism , Animals , Cell Membrane/ultrastructure , Corpus Striatum/drug effects , Corpus Striatum/ultrastructure , Fatty Acids/administration & dosage , Fish Oils/administration & dosage , Male , Plant Oils/administration & dosage , Rats, Wistar , Reactive Oxygen Species/metabolism , Synaptosomes/ultrastructure
2.
ACS Chem Neurosci ; 10(1): 323-336, 2019 01 16.
Article in English | MEDLINE | ID: mdl-30141907

ABSTRACT

Worldwide, every year there is an increase in the number of people exposed to inorganic arsenic (iAs) via drinking water. Human populations present impaired cognitive function as a result of prenatal and childhood iAs exposure, while studies in animal models demonstrate neurobehavioral deficits accompanied by neurotransmitter, protein, and enzyme alterations. Similar impairments have been observed in close association with Alzheimer's disease (AD). In order to determine whether iAs promotes the pathophysiological progress of AD, we used the 3xTgAD mouse model. Mice were exposed to iAs in drinking water from gestation until 6 months (As-3xTgAD group) and compared with control animals without arsenic (3xTgAD group). We investigated the behavior phenotype on a test battery (circadian rhythm, locomotor behavior, Morris water maze, and contextual fear conditioning). Adenosine triphosphate (ATP), reactive oxygen species, lipid peroxidation, and respiration rates of mitochondria were evaluated, antioxidant components were detected by immunoblots, and immunohistochemical studies were performed to reveal AD markers. As-3xTgAD displayed alterations in their circadian rhythm and exhibited longer freezing time and escape latencies compared to the control group. The bioenergetic profile revealed decreased ATP levels accompanied by the decline of complex I, and an oxidant state in the hippocampus. On the other hand, the cortex showed no changes of oxidant stress and complex I; however, the antioxidant response was increased. Higher immunopositivity to amyloid isoforms and to phosphorylated tau was observed in frontal cortex and hippocampus of exposed animals. In conclusion, mitochondrial dysfunction may be one of the triggering factors through which chronic iAs exposure exacerbates brain AD-like pathology.


Subject(s)
Alzheimer Disease/chemically induced , Alzheimer Disease/metabolism , Arsenic/toxicity , Energy Metabolism/physiology , Hippocampus/metabolism , Maze Learning/physiology , Alzheimer Disease/genetics , Amyloid beta-Peptides/genetics , Animals , Disease Models, Animal , Energy Metabolism/drug effects , Female , Hippocampus/drug effects , Hippocampus/pathology , Humans , Male , Maze Learning/drug effects , Mice , Mice, Transgenic , Presenilin-1/genetics , tau Proteins/genetics
3.
Biol Trace Elem Res ; 162(1-3): 211-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25319005

ABSTRACT

Quinolinic acid (QUIN) striatal injection in rat reproduces the main neurochemical features of Huntington's disease (HD), including oxidative damage. In this study, we evaluated the effect of a copper (Cu) supplement in drinking water (90 ppm Cu, 28 days) on the QUIN-induced HD model in the rat. Copper exposure caused no signs of liver toxicity; however, it produced significant Cu accumulation in striatum. It is noteworthy that QUIN also caused increased striatal Cu content; when the supplement was administered to animals with QUIN-injury, an even higher metal striatal accumulation was observed. Cu pre-treatment preserved striatal gamma-aminobutyric acid (GABA) content, which was reduced by QUIN intrastriatal injection. Similarly, apomorphine-induced circling behavior was reduced in Cu-pretreated QUIN-damaged rats. Metal supplement in drinking water prevented both lipid peroxidation and reactive oxygen species (ROS) formation caused by QUIN in striatum. In Cu-treated groups, superoxide dismutase-1 (SOD1) activity showed a significant increase, while SOD2 activity was slightly enhanced. Although the pathophysiological role for higher Cu levels in patients with HD and in experimental models of the disease is not fully understood, results in the present study suggest that Cu oral intake stimulates anti-oxidant defenses, an effect that may be a potential factor for reducing the progression of HD.


Subject(s)
Copper/therapeutic use , Huntington Disease/drug therapy , Huntington Disease/metabolism , Animals , Apomorphine/toxicity , Copper/pharmacology , Disease Models, Animal , Huntington Disease/chemically induced , Lipid Peroxidation/drug effects , Male , Oxidative Stress/drug effects , Quinolinic Acid/toxicity , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Superoxide Dismutase/metabolism , gamma-Aminobutyric Acid/metabolism
4.
Rev Invest Clin ; 61(5): 405-11, 2009.
Article in English | MEDLINE | ID: mdl-20184101

ABSTRACT

INTRODUCTION: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the presence of motor disturbances, derived from the striatal dopamine depletion. Previously, we reported that CuSO4 pretreatment blocked an oxidative stress marker (lipid peroxidation) and prevented the striatal dopamine depletion induced by the administration of the 1-methyl-4-phenylpiridinium (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a model of PD. OBJECTIVE: . To determine if tyrosine hydroxylase (TH), the rate-limiting synthetic enzyme of dopamine, is implicated in the neuroprotective effect of CuSO4 pretreatment, and if this neuroprotective effect is able to prevent the hypokinetic state (measured as spontaneous locomotor activity, SLA) induced by the experimental model of PD. MATERIAL AND METHODS: C57 Black/6J mice received a single dose of CuSO4 (2.5 mg/kg, i.p.) either 16 or 24 h before the administration of MPP+ (18 microg/3 microl, i.c.v.). Twenty four hours later, mice SLA was registered and animals sacrificed. Striatal L-DOPA accumulation derived from the administration of a central dopamine descarboxilase inhibitor was evaluated, a strategy considered as a reliable indirect analysis of tyrosine hydroxylase activity (THA). RESULTS: Administration of, MPP+ decreased SLA (-52%; p = 0.003) as compared to control group values, whereas those mice pretreated with CuSO4 16 h before MPP+, increased SLA by 47% as compared with control group (p = 0.015). Mice pretreated with CuSO4 24 h before MPP+, also showed a statistically significant increase in SLA (71%; p = 0.02), when compared with control group. As a consequence of MPP+ administration, THA was also reduced as compared to control group values (32%; p < 0.05). Reduction of THA was blocked when mice were pretreated with CuSO4 16 h before MPP+. Moreover, mice receiving the CuSO4 24 h before MPP+ showed a significant increase (38%; p < 0.05) in THA when compared with control group. CONCLUSION: Results suggest that preservation of THA participates in the neuroprotective effects derived from the copper supplementation, a phenomenon that avoid the hypokinetic state induced by the MPP+ experimental model of PD.


Subject(s)
Copper Sulfate/therapeutic use , Disease Models, Animal , Parkinson Disease/drug therapy , Tyrosine 3-Monooxygenase/metabolism , Animals , Male , Mice , Mice, Inbred C57BL , Parkinson Disease/enzymology , Parkinson Disease/physiopathology
5.
Neurochem Int ; 45(8): 1175-83, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15380627

ABSTRACT

Excitotoxicity elicited by overactivation of N-methyl-D-aspartate receptors is a well-known characteristic of quinolinic acid-induced neurotoxicity. However, since many experimental evidences suggest that the actions of quinolinic acid also involve reactive oxygen species formation and oxidative stress as major features of its pattern of toxicity, the use of antioxidants as experimental tools against the deleterious effects evoked by this neurotoxin becomes more relevant. In this work, we investigated the effect of a garlic-derived compound and well-characterized free radical scavenger, S-allylcysteine, on quinolinic acid-induced striatal neurotoxicity and oxidative damage. For this purpose, rats were administered S-allylcysteine (150, 300 or 450 mg/kg, i.p.) 30 min before a single striatal infusion of 1 microl of quinolinic acid (240 nmol). The lower dose (150 mg/kg) of S-allylcysteine resulted effective to prevent only the quinolinate-induced lipid peroxidation (P < 0.05), whereas the systemic administration of 300 mg/kg of this compound to rats decreased effectively the quinolinic acid-induced oxidative injury measured as striatal reactive oxygen species formation (P < 0.01) and lipid peroxidation (P < 0.05). S-Allylcysteine (300 mg/kg) also prevented the striatal decrease of copper/zinc-superoxide dismutase activity (P < 0.05) produced by quinolinate. In addition, S-allylcysteine, at the same dose tested, was able to reduce the quinolinic acid-induced neurotoxicity evaluated as circling behavior (P < 0.01) and striatal morphologic alterations. In summary, S-allylcysteine ameliorates the in vivo quinolinate striatal toxicity by a mechanism related to its ability to: (a) scavenge free radicals; (b) decrease oxidative stress; and (c) preserve the striatal activity of Cu,Zn-superoxide dismutase (Cu,Zn-SOD). This antioxidant effect seems to be responsible for the preservation of the morphological and functional integrity of the striatum.


Subject(s)
Antioxidants/pharmacology , Cysteine/analogs & derivatives , Cysteine/pharmacology , Garlic/chemistry , Neurotoxicity Syndromes/prevention & control , Oxidative Stress/drug effects , Quinolinic Acid/antagonists & inhibitors , Quinolinic Acid/toxicity , Animals , Behavior, Animal/drug effects , Blotting, Western , Body Weight , Glutathione Peroxidase/metabolism , Lipid Peroxidation/drug effects , Male , Neostriatum/drug effects , Neostriatum/enzymology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Superoxide Dismutase/metabolism
6.
Eur J Pharmacol ; 489(3): 197-202, 2004 Apr 12.
Article in English | MEDLINE | ID: mdl-15087243

ABSTRACT

The effects of S-allylcysteine on oxidative damage and spatial learning and memory deficits produced by an intrahippocampal injection of amyloid-beta peptide 25-35 (Abeta(25-35)) in rats were investigated. The formation of reactive oxygen species, lipid peroxidation and the activities of the antioxidant enzymes superoxide dismutase and glutathione peroxidase were all measured in hippocampus 120 min after Abeta(25-35) injection (1 microl of 100 microM solution), while learning and memory skills were evaluated 2 and 35 days after the infusion of Abeta(25-35) to rats, respectively. Abeta(25-35) increased both reactive oxygen species and lipid peroxidation, whereas pretreatment with S-allylcysteine (300 mg/kg, i.p.) 30 min before peptide injection decreased both of these markers. In addition, Abeta(25-35)-induced incorrect learning responses were prevented in most of trials by S-allylcysteine. In contrast, enzyme activities were found unchanged in all groups tested. Findings of this work: (i) support the participation of reactive oxygen species in Abeta(25-35)-induced hippocampal toxicity and learning deficits; and (ii) suggest that the protective effects of S-allylcysteine were related to its ability to scavenge reactive oxygen species.


Subject(s)
Amyloid beta-Peptides/adverse effects , Cysteine/analogs & derivatives , Cysteine/therapeutic use , Hippocampus/drug effects , Hippocampus/metabolism , Oxidative Stress/drug effects , Amyloid beta-Peptides/administration & dosage , Animals , Cysteine/administration & dosage , Cysteine/chemical synthesis , Drug Administration Schedule , Fluoresceins , Garlic/chemistry , Glutathione Peroxidase/chemistry , Glutathione Peroxidase/metabolism , Hippocampus/physiopathology , Injections, Intraperitoneal , Learning Disabilities/chemically induced , Learning Disabilities/prevention & control , Lipid Peroxidation/drug effects , Lipid Peroxidation/physiology , Male , Maze Learning/drug effects , Maze Learning/physiology , Memory/drug effects , Rats , Rats, Wistar , Reactive Oxygen Species/antagonists & inhibitors , Reactive Oxygen Species/chemistry , Reactive Oxygen Species/metabolism , Spatial Behavior/drug effects , Spatial Behavior/physiology , Superoxide Dismutase/chemistry , Superoxide Dismutase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL